The NODE-202 Study (Study of Etripamil Nasal Spray in Pediatric Patients)
- Conditions
- Paroxysmal supraventricular tachycardia (PSVT)MedDRA version: 20.0Level: LLTClassification code: 10034044Term: Paroxysmal supraventricular tachycardia Class: 10007541Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
- Registration Number
- CTIS2022-500319-38-00
- Lead Sponsor
- Milestone Pharmaceuticals Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 60
Male or female patients: a) Part 1: patients 12 to <18 years of age b) Part 2: patients 6 to <12 years of age, Body mass index (BMI) between the 5th and the 85th percentiles interpreted relative sex and age, History of PSVT documented by ECG or other monitoring modality (e.g., Holter monitor, event recorder) showing SVT involving the AV node (i.e., AVNRT or AVRT). If patient had a prior ablation for PSVT, patient must have documented evidence of PSVT post-ablation, Signed written informed consent/assent obtained, Females of childbearing potential (defined as any woman or adolescent who has begun menstruation) must additionally satisfy the following criteria: a)Negative pregnancy test at screening b)Adequate contraception, unless total abstinence is used. Adequate contraception must be used from the time of signed informed consent until the post-treatment follow-up visit. Acceptable methods include combined (estrogen and progestogen containing) or progestogen-only hormonal contraception, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide. NOTE: Patients who become a female of child-bearing potential after their screening visit must be re-assessed for these criteria before a treatment visit., Willing and able to comply with study procedures.
History or presence of any of the following at the screening visit: a) Patients with a history of atrial arrhythmia that does not involve the AV node as part of the tachycardia circuit (e.g., atrial fibrillation, atrial flutter, atrial tachycardia) are not eligible; b) Permanent junctional reciprocating tachycardia; c) Ventricular pre-excitation (e.g., delta wave on ECG, Wolff Parkinson White syndrome); d) Second- or third-degree AV block; e) Sick sinus syndrome or clinically significant bradycardia (<50 bpm or equivalent in this patient population) on the resting ECG; f) Ventricular tachycardia; g) Long QT syndrome; h) Major structural heart disease (e.g., Ebstein’s anomaly, corrected congenital heart disease) or symptoms of congestive heart failure (New York Heart Association class II to IV)., Evidence of impaired liver function (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] >3 x upper limit of normal for age and gender) at the Screening Visit, Evidence of End-Stage Renal Disease as determined by an estimated glomerular filtration rate assessed at the Screening Visit (using revised bedside Schwartz equation) of <15 mL/min/1.73m2, or requiring hemodialysis, Treatment with any of the following that cannot or will not be discontinued during study participation: a) Any investigational drug within 60 days prior to study drug administration; b) IV beta-adrenergic blocking drugs (e.g., propranolol, esmolol), calcium channel blocking drugs (e.g., verapamil, diltiazem) or amiodarone within 24 hours prior to study drug administration; c) Oral amiodarone within 30 days prior to study drug administration; d) Class I or III antiarrhythmic agents (e.g., flecainide, propafenone, sotalol) within five half-lives prior to study drug administration; e) Any other drug that has a contraindication with verapamil., Known hypersensitivity to verapamil or to any of the excipients of the study drug, Any other significant co-morbid condition that may have a negative impact on the patient’s participation in the study or likely to result in non-compliance, History of hyperthyroidism, Current pregnancy or breastfeeding
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To demonstrate the efficacy of a single intranasal (IN) dose of etripamil nasal spray (NS) in terminating a spontaneous episode of PSVT in<br>• Part 1: Patients aged 12 to <18 years, and <br>• Part 2: Patients aged 6 to <12 years.;Secondary Objective: To evaluate the safety and tolerability of etripamil nasal spray (NS) in Patients aged 12 to <18 years (Part 1) and Patients aged 6 to <12 years (Part 2);Primary end point(s): Efficacy: The percentage of patients converting to SR in the first 15 minutes after administration of etripamil NS. A successful conversion is defined as conversion of PSVT to SR that is maintained for at least 30 seconds.
- Secondary Outcome Measures
Name Time Method Secondary end point(s):Time to termination of the PSVT episode and conversion to sinus rhythm (SR);Secondary end point(s):Percentage of patients requiring additional medical intervention treatment for the PSVT episode in the first 15 minutes after study drug administration;Secondary end point(s):Frequency of AEs;Secondary end point(s):Local (administration site) tolerability;Secondary end point(s):Post-dose changes in vital signs (HR and BP)